4D Molecular Therapeutics Inc (FDMT) Stock Price, Quote & News

Company Profile

4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. Its lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degene...

Industry: Biotechnology

Sector: Healthcare

Phone: 510 505 2680

Website: www.4dmoleculartherapeutics.com

Address:

5858 Horton Street, Suite 455, EmeryVille, United States

eeyore1 Oct. 3 at 6:55 PM

$FDMT Yes! Ia-Ia-Ia...

0 · Reply

caronte Oct. 3 at 6:54 PM

$FDMT

0 · Reply

eeyore1 Oct. 3 at 6:51 PM

$FDMT Very good job, caronte! No $40 and then $100 - this is a big progress. Medication helps.

0 · Reply

caronte Oct. 3 at 6:49 PM

$FDMT small volume. shorts will have to cover.

0 · Reply

senior_nurse Oct. 3 at 6:42 PM

$FDMT caronte, immediately shout out $40 then $100+, and then squizze those shorts like a lemon.

0 · Reply

senior_nurse Oct. 3 at 6:38 PM

$FDMT Eh, caronte - I told the intern to give you 10mg instead of 5 next time

0 · Reply

nurse_intern Oct. 3 at 5:23 PM

$FDMT It's all your fault, caronte. If it goes today below 8.5

0 · Reply

nurse_intern Oct. 3 at 5:08 PM

$FDMT caronte, what have you done? I told you to take your medicine on time. You did not, came up with a useles slogan again, and crashed this lovely stock.

0 · Reply

caronte Oct. 3 at 4:38 PM

$FDMT

0 · Reply

ReturnOfEsquire Oct. 3 at 4:26 PM

$FDMT Hit piece with zero mention of the science. https://finance.yahoo.com/news/4d-molecular-therapeutics-nasdaq-fdmt-110132014.html

1 · Reply

4D Molecular Therapeutics: This Gene Therapy Company May Soon Surprise Investors

Sep 12, 2025, 4:05 PM EDT - 22 days ago

4DMT Announces New Employment Inducement Grants

Sep 9, 2025, 6:13 PM EDT - 25 days ago

4D Molecular Therapeutics, Inc. (FDMT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 2, 2025, 8:00 AM EDT - 4 weeks ago

4DMT Announces Leadership Expansion with Proven Late-Stage Executives to Drive 4D-150 Execution and BLA Readiness

Aug 25, 2025, 8:00 AM EDT - 5 weeks ago

4DMT to Participate in Upcoming Investor Conferences

Aug 11, 2025, 8:00 AM EDT - 7 weeks ago

4DMT Reports Second Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

Aug 6, 2025, 8:00 AM EDT - 2 months ago

4DMT to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 1, 2025, 10:29 AM EDT - 2 months ago

4D Molecular Therapeutics Rallies On Heels Of Diabetes-Related Vision Study

Jul 31, 2025, 4:05 PM EDT - 2 months ago

4DMT Presents Positive 60-Week Results from 4D-150 SPECTRA Clinical Trial in DME and Regulatory Update

Jul 24, 2025, 8:00 AM EDT - 2 months ago

4DMT Announces Presentations at 43rd Annual Scientific Meeting of the American Society of Retina Specialists

Jul 2, 2025, 4:05 PM EDT - 3 months ago

4DMT Announces Accelerated 4D-150 Phase 3 Development in Wet AMD and Streamlined Organization to Drive Late-Stage Execution

May 8, 2025, 4:05 PM EDT - 5 months ago

4DMT Reports First Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

May 1, 2025, 8:00 AM EDT - 5 months ago

4DMT Announces RMAT Designation Granted by FDA for 4D-150 for DME

Mar 10, 2025, 8:00 AM EDT - 7 months ago

4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD

Feb 28, 2025, 4:05 PM EST - 7 months ago

4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

Feb 18, 2025, 2:33 PM EST - 8 months ago

4D Molecular Therapeutics: A Smart Bet On Long-Term VEGF Suppression

Feb 10, 2025, 10:26 AM EST - 8 months ago

Eye Disease Focused 4D Molecular Therapeutics Lays Out 52-Week Results From Wet AMD Study

Feb 8, 2025, 2:30 PM EST - 8 months ago

4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program

Nov 13, 2024, 4:05 PM EST - 11 months ago

4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

Nov 4, 2024, 11:00 AM EST - 11 months ago

4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Encourages Investor Participation

Nov 2, 2024, 11:00 AM EDT - 1 year ago

4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Investors To Reach Out

Oct 30, 2024, 11:00 AM EDT - 1 year ago

4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Impacted Investors To Reach Out

Oct 28, 2024, 11:00 AM EDT - 1 year ago

4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Investors To Take Part

Oct 18, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Encourages Investors To Help Investigate 4D Molecular Therapeutics Inc For Possible Securities Fraud

Oct 16, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Urges Investor Participation In An Investigation Into 4D Molecular Therapeutics Inc For Securities Fraud

Oct 14, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Urges Investors To Help Investigate Whether 4D Molecular Therapeutics Inc Committed Securities Fraud

Oct 12, 2024, 11:00 AM EDT - 1 year ago

4D Molecular Therapeutics Inc Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Impacted Investors To Reach Out

Oct 10, 2024, 11:00 AM EDT - 1 year ago

4D Molecular Therapeutics Inc Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Investor Participation

Oct 8, 2024, 11:00 AM EDT - 1 year ago

4D Molecular Therapeutics Inc Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Affected Investors To Reach Out

Oct 6, 2024, 11:00 AM EDT - 1 year ago

4D Molecular Therapeutics, Inc. Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Affected Investors To Reach Out

Oct 4, 2024, 12:35 PM EDT - 1 year ago

4D Molecular Therapeutics: Market Expects Wet AMD Gene Therapy Failure - I'm Not So Sure

Oct 4, 2024, 11:00 AM EDT - 1 year ago

4D Molecular Therapeutics, Inc. Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Impacted Investors To Reach Out

$Shareholders Are Encouraged To Join The Schall Law Firm's Inquiry Into 4D Molecular Therapeutics Inc For Securities Related Infractions$

Oct 3, 2024, 11:00 AM EDT - 1 year ago

Shareholders Are Encouraged To Join The Schall Law Firm's Inquiry Into 4D Molecular Therapeutics Inc For Securities Related Infractions

Sep 30, 2024, 11:00 AM EDT - 1 year ago

4D Molecular Therapeutics, Inc. Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Invites Affected Investors To Reach Out

Sep 27, 2024, 11:00 AM EDT - 1 year ago

Shareholders Are Urged To Take Part In The Schall Law Firm's Inquiry Into 4D Molecular Therapeutics Inc For Violating Securities Laws

Sep 26, 2024, 11:00 AM EDT - 1 year ago

4D Molecular Therapeutics, Inc. Is Being Investigated For Securities Fraud And The Schall Law Firm Invites Affected Investors To Join

Sep 24, 2024, 11:00 AM EDT - 1 year ago

4D Molecular Therapeutics, Inc. Is Being Investigated For Securities Fraud And Investors Are Urged To Assist The Schall Law Firm

$The Schall Law Firm Invites Shareholder Participation In An Inquiry Into 4D Molecular Therapeutics Inc For Securities Related Infractions$

Sep 23, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Invites Shareholder Participation In An Inquiry Into 4D Molecular Therapeutics Inc For Securities Related Infractions

Sep 23, 2024, 8:00 AM EDT - 1 year ago

4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference

eeyore1 Oct. 3 at 6:55 PM

$FDMT Yes! Ia-Ia-Ia...

0 · Reply

caronte Oct. 3 at 6:54 PM

$FDMT

0 · Reply

eeyore1 Oct. 3 at 6:51 PM

$FDMT Very good job, caronte! No $40 and then $100 - this is a big progress. Medication helps.

0 · Reply

caronte Oct. 3 at 6:49 PM

$FDMT small volume. shorts will have to cover.

0 · Reply

senior_nurse Oct. 3 at 6:42 PM

$FDMT caronte, immediately shout out $40 then $100+, and then squizze those shorts like a lemon.

0 · Reply

senior_nurse Oct. 3 at 6:38 PM

$FDMT Eh, caronte - I told the intern to give you 10mg instead of 5 next time

0 · Reply

nurse_intern Oct. 3 at 5:23 PM

$FDMT It's all your fault, caronte. If it goes today below 8.5

0 · Reply

nurse_intern Oct. 3 at 5:08 PM

$FDMT caronte, what have you done? I told you to take your medicine on time. You did not, came up with a useles slogan again, and crashed this lovely stock.

0 · Reply

caronte Oct. 3 at 4:38 PM

$FDMT

0 · Reply

ReturnOfEsquire Oct. 3 at 4:26 PM

$FDMT Hit piece with zero mention of the science. https://finance.yahoo.com/news/4d-molecular-therapeutics-nasdaq-fdmt-110132014.html

1 · Reply

Emremumcu01 Oct. 3 at 3:53 PM

$FDMT very strange price action .. it’s like they are trying to keep it at the same price.

0 · Reply

nurse_intern Oct. 3 at 2:21 PM

$FDMT caronte, swallow your 5 mg of lorazepam already. You’re on the verge of another epic meltdown over your mythical 40 short-term and 100+ long-term obsession — like the world’s waiting for your grand market revelation

0 · Reply

caronte Oct. 3 at 1:59 PM

$FDMT

0 · Reply

Emremumcu01 Oct. 2 at 7:18 PM

$FDMT late push coming I feel It

0 · Reply

piglet1 Oct. 1 at 11:41 PM

$FDMT The main catalyst 4FRONT‑1 (Phase 3 for 4D‑150 in wet AMD) 52‑week topline data expected in H1 2027 (accelerated from previously H2 2027) Is anyone willing to wait?

1 · Reply

piglet1 Oct. 1 at 11:33 PM

$FDMT 11% is enough to spark a squeeze only if combined with low liquidity and a strong catalyst. On its own, it’s not “high short interest” by squeezing standards

0 · Reply

piglet1 Oct. 1 at 11:27 PM

$FDMT Here we go again. Nurse, help!

0 · Reply

caronte Oct. 1 at 11:03 PM

$FDMT all shorts will be squeezed like a Lemmon stay long

0 · Reply

eeyore1 Oct. 1 at 7:32 PM

$FDMT House Rules: Posting the same or very similar messages or links multiple times is spam

0 · Reply

ReturnOfEsquire Oct. 1 at 7:06 PM

$FDMT Green...

2 · Reply

BillionerOfKing Oct. 1 at 4:38 PM

$FDMT Current Stock Price: $8.53 Contracts to trade: $10 FDMT Oct 17 2025 Call Entry: $0.23 Exit: $0.42 ROI: 88% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

piglet1 Oct. 1 at 4:21 PM

$FDMT FDA wouldn't accept new drug applications during government shutdown.

0 · Reply

Market Cap	404.91M
Revenue (ttm)	40,000.00
Net Income (ttm)	-160.87M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-402,175.00%
Debt to Equity Ratio	0.00

Volume	410,300
Avg Vol	1,406,710
Day's Range	N/A - N/A
Shares Out	46.70M
Stochastic %K	69%
Beta	2.93
Analysts	Strong Sell
Price Target	$28.78